(Q28301602)

10

Farhad Ravandi

0 references

Maher Albitar

5

Maher Albitar

0 references

Jean-Pierre J Issa

2

Jean-Pierre J Issa

0 references

Saba Hussain

16

Hussain Saba

0 references

Virginia M Klimek

7

Virginia Klimek

0 references

John DiPersio

6

John DiPersio

0 references

Craig S Rosenfeld

3

Craig S Rosenfeld

0 references

Azra Raza

15

Azra Raza

0 references

James Richard Slack

8

James Slack

0 references

Lanlan Shen

12

Lanlan Shen

0 references

Stephen D Nimer

13

Stephen D Nimer

0 references

Richard D Leavitt

14

Richard Leavitt

0 references

author name string

John M Bennett

4

0 references

Carlos de Castro

9

0 references

Richard Helmer

Proposals for the classification of the myelodysplastic syndromes

11

0 references

language of work or name

English

0 references

publication date

15 April 2006

0 references

published in

Cancer

0 references

volume

106

0 references

issue

8

0 references

page(s)

1794-803

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

CpG-rich islands and the function of DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

Gene silencing in cancer in association with promoter hypermethylation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

Expression of the beta 4 integrin subunit induces monocytic differentiation of 32D/v-Abl cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

Contribution of β-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

Decitabine in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021

Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21792

7 January 2021